Committee for Advanced Therapies (CAT) meeting with interested parties

CAT engages in active dialogue with its interested parties on a regular basis. During its October 2021 annual meeting CAT and its interested parties discussed the following scientific topics: CAT activities, ATMP lifecycle support and patient access; comprehensiveness of clinical data in marketing authorisations; GMO/ERA in clinical trials and marketing authorisations; EMA-FDA parallel advice; The new HTA regulation; ATMPs and Real World Evidence. Other issues and questions from the participating interested parties were also addressed.